Actor portrayals. IMPORTANT SAFETY INFORMATION ( cont’d ) particularly those with risk factors for skin cancer. Advise patients to avoid sunlamps and minimize exposure to sunlight by wearing sun-protective clothing or using broad-spectrum sunscreen. Immunizations Prior to ANZUPGO treatment, complete all age-appropriate vaccinations as recommended by current immunization guidelines, including herpes zoster vaccinations. Avoid vaccination with live vaccines immediately prior to, during, and immediately after ANZUPGO treatment. Potential Risks Related to JAK Inhibition It is not known whether ANZUPGO may be associated with the observed or potential adverse reactions of JAK inhibition. In a large, randomized, postmarketing safety trial of an oral JAK inhibitor in combination with methotrexate in rheumatoid arthritis (RA), patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events (MACE), overall thrombosis, deep venous thrombosis (DVT), pulmonary embolism (PE), and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK References: 1. ANZUPGO. Prescribing information. LEO Pharma Inc. 2. Dubin C, et al. Ther Clin Risk Manag . 2020;16:1319-1332. doi:10.2147/TCRM.S292504 The LEO Pharma logo and ANZUPGO® are registered trademarks of LEO Pharma A/S. © 2025 LEO Pharma Inc. All rights reserved. MAT-81075 July 2025 inhibitor compared to those treated with TNF blockers. ANZUPGO is not indicated for use in RA. Treatment with oral and topical JAK inhibitors has been associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Adverse Reactions Adverse reactions reported in ≤1% of subjects were application site pain, paresthesia, pruritus, erythema, and bacterial skin infections, including finger cellulitis, paronychia, other skin infections, leukopenia, and neutropenia. Lactation To minimize potential infant exposure, advise breastfeeding women to avoid direct contact with the nipple and surrounding area immediately after applying ANZUPGO to the hands and/or wrists. Please see additional Important Safety Information and Brief Summary of Prescribing Information on the following pages.
Journal of Clinical and Aesthetic Dermatology Chronic Hand Eczema: Understanding a Complex and Persistent Inflammatory Disease: S-3
